On May 29, 2024, Thomas Rogers, EVP, Chief Strategy and Business Development Officer of McKesson Corporation (NYSE:MCK), sold 922 shares of the company's stock. As detailed in the SEC filing, the transaction was performed at $556.33 per share. Following this transaction, the insider now owns 7,776 shares of McKesson Corporation stock.
McKesson Corp is a global leader in healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology, and continues to play a key role in pharmaceuticals and medical supplies.
Over the past year, Thomas Rogers has sold a total of 8,503 shares and hasn't bought any shares in the company. This recent sale is part of a broader trend we are seeing within the company, which has seen 32 insider sales and no insider purchases in the past year.
On the day of the sale, McKesson's stock was trading at $556.33, giving the company a market capitalization of approximately $73.23 billion. The price-to-earnings ratio of 25.17 is higher than the industry average of 17.33 and the company's historical average.
According to GF Value, the intrinsic value of McKesson Corp shares is estimated at $469.33, with a price to GF Value ratio of 1.19 indicating that the stock is moderately overvalued.
GF Value is calculated by considering historical trading multiples such as price-to-earnings multiples, price-to-sales multiples, price-to-book multiples and price-to-free cash flow multiples, as well as a GuruFocus adjustment factor based on historical earnings and growth, and Morningstar analyst estimates of future earnings performance.
This insider sale at McKesson Corp provides an interesting data point for investors tracking insider activity and company valuation metrics.
This article written by GuruFocus is intended to provide general insights and is not tailored financial advice. Our commentary is based on historical data and analyst forecasts, uses an unbiased methodology and is not intended to serve as specific investment guidance. It is not a recommendation to buy or sell stocks, nor does it take into account individual investment objectives or financial situation. Our objective is to provide long-term, fundamental data-driven analysis. Please note that our analysis may not incorporate the latest price-sensitive company announcements or qualitative information. GuruFocus has no position in the stocks mentioned herein.
This article was originally published on GuruFocus.
